Atherosclerosis
Volume 210, Issue 1 , Pages 35-40 , May 2010

The effect of PPAR-α agonism on apolipoprotein metabolism in humans

Received 9 June 2009 ,Revised 30 September 2009 ,Accepted 9 November 2009.

References 

  1. MacKay J, Mensah GA. The atlas of heart disease and stroke. Geneva, Switzerland: World Health Organization; 2004;
  2. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–2497
  3. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?. Arterioscler Thromb Vasc Biol. 2008;28:39–46
  4. Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem. 2008;54:1038–1045
  5. Ge H, Cha JY, Gopal H, et al. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res. 2005;46:1484–1490
  6. Vu-Dac N, Gervois P, Jakel H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem. 2003;278:17982–17985
  7. Dunbar RL, Rader DJ. Demystifying triglycerides: a practical approach for the clinician. Cleve Clin J Med. 2005;72:661–680
  8. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987;83(5B):9–20
  9. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007;297:1362–1373
  10. Terra SG, Francone OL, Contant CF, Gao X, Lewin AJ, Nguyen TT. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. Am J Cardiol. 2008;102:434–439
  11. Berman M, Hall M, Levy RI, et al. Metabolism of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects. J Lipid Res. 1978;19:38–56
  12. Shepherd J, Packard CJ, Stewart JM, et al. Apolipoprotein A and B (sf 100–400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest. 1984;74:2164–2177
  13. Turner PR, Cortese C, Wootton R, Marenah C, Miller NE, Lewis B. Plasma apolipoprotein B metabolism in familial type III dysbetalipoproteinaemia. Eur J Clin Invest. 1985;15:100–112
  14. Packard CJ, Clegg RJ, Dominiczak MH, Lorimer AR, Shepherd J. Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J Lipid Res. 1986;27:930–938
  15. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003;52:803–811
  16. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res. 2004;45:174–185
  17. Ruel IL, Lamarche B, Mauger JF, et al. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. Arterioscler Thromb Vasc Biol. 2005;25:2600–2607
  18. Tremblay AJ, Lamarche B, Ruel IL, et al. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. Atherosclerosis. 2006;188:203–212
  19. Hogue JC, Lamarche B, Deshaies Y, et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism. 2008;57:246–254
  20. Shepherd J, Caslake MJ, Lorimer AR, Vallance BD, Packard CJ. Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis. 1985;5:162–168
  21. Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins. JAMA. 1985;253:2398–2403
  22. Stewart JM, Packard CJ, Lorimer AR, Boag DE, Shepherd J. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis. 1982;44:355–365
  23. Malmendier CL, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis. 1985;55:161–169
  24. Gaw A, Packard CJ, Caslake MJ, et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis. 1994;108:137–148
  25. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb. 1993;13:702–711
  26. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest. 1985;75:1702–1712
  27. Ginsberg HN. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am J Med. 1987;83(5B):66–70
  28. Millar JS, Duffy D, Gadi R, et al. Treatment with a potent and selective PPAR-α agonist, LY518674, significantly increases apoA-I and apoA-II production rates in patients with metabolic syndrome despite no change in HDL. Arteriosler Thromb Vasc Biol. 2009;29:140–146
  29. Hahn SE, Goldberg DM. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol. 1992;43:625–633
  30. Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes. 2002;51:3486–3491
  31. Schneider J, Schaefer S, Lettgen B, Keiper T, Nawroth P, Dugi K. Siblings with hepatosplenomegaly and lipoprotein lipase deficiency. Lancet. 2002;360:1150
  32. Demant T, Gaw A, Watts GF, et al. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia. J Lipid Res. 1993;34:147–156
  33. Naruszewicz M, Mirkiewicz E, Kłosiewicz-Latoszek L. Modification of low density lipoproteins from hypertriglyceridemic patients by macrophages in vitro and the effect of bezafibrate treatment. Atherosclerosis. 1989;79:261–265
  34. Nguyen TT, Kruckeberg KE, O’Brien JF, et al. Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]. J Clin Endocrinol Metab. 2000;85:4354–4358
  35. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997;17:3542–3556
  36. Schneider A, Stange EF, Ditschuneit HH, Ditschuneit H. Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis. 1985;56:257–262
  37. Demant T, Carlson LA, Holmquist L, et al. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res. 1988;29:1603–1611
  38. Taskinen MR, Sullivan DR, Ehnholm C, et al. FIELD study investigators. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol. 2009;29:950–955
  39. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 1993;91:1743–1752

PII: S0021-9150(09)00967-8

doi: 10.1016/j.atherosclerosis.2009.11.010

Atherosclerosis
Volume 210, Issue 1 , Pages 35-40 , May 2010

Article Tools

* Image Usage & Resolution